This clinical trial is focused on studying a condition called Juvenile Psoriatic Arthritis (JPsA), which affects children and teenagers. JPsA is a type of arthritis that not only causes joint pain and swelling but also involves skin problems similar to psoriasis, such as red, scaly patches. The trial will test a medication called deucravacitinib, also known by its code name BMS-986165. This medication is taken as a film-coated tablet and is being compared to a placebo to see if it can effectively manage the symptoms of JPsA in young participants.

The purpose of the study is to determine if deucravacitinib is more effective than a placebo in treating JPsA in children and adolescents aged 5 to 18. Participants will take the medication or placebo orally over a period of time, and researchers will monitor how long it takes for the first flare-up of the disease to occur. The study will also assess how much the disease improves, how many participants experience a reduction in symptoms, and how well the medication is tolerated, including its taste and ease of swallowing.

Throughout the study, researchers will keep track of any side effects and monitor the overall safety of deucravacitinib. They will also evaluate the amount of the medication in the body and its impact on the disease. The trial aims to provide valuable information on the effectiveness and safety of deucravacitinib for managing Juvenile Psoriatic Arthritis in young patients.